J T Schiller

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi Understanding and learning from the success of prophylactic human papillomavirus vaccines
    John T Schiller
    National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nat Rev Microbiol 10:681-92. 2012
  2. ncbi Overcoming antigen masking of anti-amyloidbeta antibodies reveals breaking of B cell tolerance by virus-like particles in amyloidbeta immunized amyloid precursor protein transgenic mice
    Qingyou Li
    Department of Pharmacology University of South Florida, Tampa FL 33612 4799, USA
    BMC Neurosci 5:21. 2004
  3. ncbi Papillomavirus-like particle based vaccines: cervical cancer and beyond
    J T Schiller
    National Cancer Institute, Bethesda, MD, USA
    Expert Opin Biol Ther 1:571-81. 2001
  4. ncbi An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results
    John T Schiller
    Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, MD, USA
    Vaccine 26:K53-61. 2008
  5. ncbi Delivering on the promise: HPV vaccines and cervical cancer
    John T Schiller
    National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    Nat Rev Microbiol 2:343-7. 2004
  6. ncbi Developing HPV virus-like particle vaccines to prevent cervical cancer: a progress report
    J T Schiller
    Laboratory of Cellular Oncology, DBS, Building 36, RM 1D32, Bethesda, MD 20892, USA
    J Clin Virol 19:67-74. 2000
  7. ncbi Papillomavirus-like particle vaccines for cervical cancer
    J T Schiller
    Laboratory of Cellular Oncology, National Cancer Institute, Bldg 36, RM 1D32, Bethesda, MD 20892, USA
    Mol Med Today 5:209-15. 1999
  8. ncbi Chapter 17: Second generation HPV vaccines to prevent cervical cancer
    John T Schiller
    Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, MD 20892, USA
    Vaccine 24:S3/147-53. 2006
  9. ncbi Prospects for cervical cancer prevention by human papillomavirus vaccination
    John T Schiller
    Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA
    Cancer Res 66:10229-32. 2006
  10. ncbi Characterization of a human papillomavirus type 16 variant-dependent neutralizing epitope
    R B Roden
    Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, Maryland 20892, USA
    J Virol 71:6247-52. 1997

Detail Information

Publications87

  1. ncbi Understanding and learning from the success of prophylactic human papillomavirus vaccines
    John T Schiller
    National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nat Rev Microbiol 10:681-92. 2012
    ....
  2. ncbi Overcoming antigen masking of anti-amyloidbeta antibodies reveals breaking of B cell tolerance by virus-like particles in amyloidbeta immunized amyloid precursor protein transgenic mice
    Qingyou Li
    Department of Pharmacology University of South Florida, Tampa FL 33612 4799, USA
    BMC Neurosci 5:21. 2004
    ....
  3. ncbi Papillomavirus-like particle based vaccines: cervical cancer and beyond
    J T Schiller
    National Cancer Institute, Bethesda, MD, USA
    Expert Opin Biol Ther 1:571-81. 2001
    ..Vaccines based on this approach could potentially be effective alternatives to monoclonal antibody (mAb)-based therapies for a variety of disease targets...
  4. ncbi An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results
    John T Schiller
    Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, MD, USA
    Vaccine 26:K53-61. 2008
    ..The results of these studies have led to the approval of Gardasil and Cervarix by national regulatory agencies in a number of countries...
  5. ncbi Delivering on the promise: HPV vaccines and cervical cancer
    John T Schiller
    National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    Nat Rev Microbiol 2:343-7. 2004
  6. ncbi Developing HPV virus-like particle vaccines to prevent cervical cancer: a progress report
    J T Schiller
    Laboratory of Cellular Oncology, DBS, Building 36, RM 1D32, Bethesda, MD 20892, USA
    J Clin Virol 19:67-74. 2000
    ....
  7. ncbi Papillomavirus-like particle vaccines for cervical cancer
    J T Schiller
    Laboratory of Cellular Oncology, National Cancer Institute, Bldg 36, RM 1D32, Bethesda, MD 20892, USA
    Mol Med Today 5:209-15. 1999
    ..In addition, the strongly immunogenic characteristics of VLPs raise the possibility that they could also serve as vehicles for inducing therapeutic responses against HPV-induced neoplasia and other diseases...
  8. ncbi Chapter 17: Second generation HPV vaccines to prevent cervical cancer
    John T Schiller
    Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, MD 20892, USA
    Vaccine 24:S3/147-53. 2006
    ..Three questions need to be addressed: (1) Is there sufficient need for a second generation vaccine? (2) Are there sufficiently attractive candidates for clinical trials? (3) Is there a realistic development/commercialization path?..
  9. ncbi Prospects for cervical cancer prevention by human papillomavirus vaccination
    John T Schiller
    Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA
    Cancer Res 66:10229-32. 2006
    ..These include duration of protection, degree of cross-protection against nonvaccine types, efficacy in men, and vaccine availability to economically disadvantaged women...
  10. ncbi Characterization of a human papillomavirus type 16 variant-dependent neutralizing epitope
    R B Roden
    Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, Maryland 20892, USA
    J Virol 71:6247-52. 1997
    ..E70 to L1 virus-like particles of the two variants. A substitution at residue 282 of L1 was responsible for this differential reactivity, suggesting that this residue constitutes part of the H16.E70 epitope...
  11. ncbi Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic
    R Kirnbauer
    Laboratory of Cellular Oncology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892
    Proc Natl Acad Sci U S A 89:12180-4. 1992
    ..This type of L1 preparation might be considered as a candidate for a serological test to measure antibodies to conformational virion epitopes and for a vaccine to prevent papillomavirus infection...
  12. ncbi L1 interaction domains of papillomavirus l2 necessary for viral genome encapsidation
    M M Okun
    Laboratory of Cellular Oncology, Division of Basic Sciences, National Cancer Institute, Bethesda, Maryland 20892, USA
    J Virol 75:4332-42. 2001
    ..We conclude that the L1-binding domain located near the C terminus of L2 may bind L1 prior to completion of capsid assembly, and that both L1-binding domains of L2 are required for efficient encapsidation of the viral genome...
  13. ncbi NHPV16 VLP vaccine induces human antibodies that neutralize divergent variants of HPV16
    D V Pastrana
    Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, Maryland, 20892, USA
    Virology 279:361-9. 2001
    ..Vaccination with HPV16 114K L1 VLPs generates antibodies that should confer a similar degree of protection against all known phylogenetic branches of HPV16...
  14. ncbi Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes
    R B Roden
    Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, Maryland 20892 4040, USA
    Virology 270:254-7. 2000
    ..This suggests that unlike VLP-based prophylactic HPV vaccines, an L2 polypeptide vaccine may provide broad-spectrum protection...
  15. ncbi Papillomaviruses: prophylactic vaccine prospects
    D R Lowy
    Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, MD 20892, USA
    Biochim Biophys Acta 1423:M1-8. 1999
    ..Since prospective efficacy trials will take several years to complete, considering alternative approaches is also worthwhile...
  16. ncbi The region of the HPV E7 oncoprotein homologous to adenovirus E1a and Sv40 large T antigen contains separate domains for Rb binding and casein kinase II phosphorylation
    M S Barbosa
    Laboratory of Cellular Oncology, National Cancer Institute, NIH Bethesda, MD 20892
    EMBO J 9:153-60. 1990
    ....
  17. ncbi Papillomavirus-like particles induce acute activation of dendritic cells
    P Lenz
    Laboratory of Cellular Oncology, National Cancer Institute, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 166:5346-55. 2001
    ..These results offer a mechanistic explanation for the striking ability of papillomavirus VLP-based vaccines to induce potent T and B cell responses even in the absence of adjuvant...
  18. ncbi Human papillomavirus type 16 and risk of preinvasive and invasive vulvar cancer: results from a seroepidemiological case-control study
    A Hildesheim
    Environmental Epidemiology Branch, National Cancer Institute, Bethesda, Maryland 20892 7374, USA
    Obstet Gynecol 90:748-54. 1997
    ..To examine whether human papillomavirus (HPV) type 16 is involved in the etiology of vulvar carcinomas...
  19. ncbi Novel structural features of bovine papillomavirus capsid revealed by a three-dimensional reconstruction to 9 A resolution
    B L Trus
    Computational Bioscience and Engineering Laboratory, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 5624, USA B L T
    Nat Struct Biol 4:413-20. 1997
    ..Inter-capsomere connections approximately 10 A in diameter were clearly resolved. These link adjacent capsomeres and are reminiscent of the helical connections that stabilize polyomavirus...
  20. ncbi Seroreactivity to human papillomavirus types 16, 18, 31, and 45 virus-like particles in a case-control study of cervical squamous intraepithelial lesions
    L Wideroff
    NCI ARB, EPN 313 MSC 7344, Bethesda, MD 20892 7344, USA
    J Infect Dis 180:1424-8. 1999
    ..These data suggest that seroreactivity to a given type reflects mainly type-specific HPV infection as measured by DNA detection and may also signal past exposure to other types that are now only serologically detected...
  21. ncbi Determinants of autoantibody induction by conjugated papillomavirus virus-like particles
    Bryce Chackerian
    Laboratory of Cellular Oncology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 169:6120-6. 2002
    ....
  22. ncbi Carrageenan is a potent inhibitor of papillomavirus infection
    Christopher B Buck
    Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, Maryland, USA
    PLoS Pathog 2:e69. 2006
    ..Some of these products block HPV infectivity in vitro, even when diluted a million-fold. Clinical trials are needed to determine whether carrageenan-based products are effective as topical microbicides against genital HPVs...
  23. ncbi Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18
    Diana V Pastrana
    Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, MD 20892-4263, USA
    Virology 321:205-16. 2004
    ..The SEAP pseudovirus-based neutralization assay should be a practical method for quantifying potentially protective antibody responses in HPV natural history and prophylactic vaccine studies...
  24. ncbi Positive and negative regulation of cell proliferation by E2F-1: influence of protein level and human papillomavirus oncoproteins
    R M Melillo
    Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, Maryland 20892
    Mol Cell Biol 14:8241-9. 1994
    ....
  25. ncbi The bovine papillomavirus E5 transforming protein can stimulate the transforming activity of EGF and CSF-1 receptors
    P Martin
    Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, Maryland 20892
    Cell 59:21-32. 1989
    ..We conclude that E5 may enhance the receptor activity via inhibition of receptor down-modulation...
  26. ncbi In vivo mechanisms of vaccine-induced protection against HPV infection
    Patricia M Day
    Laboratory of Cellular Oncology, National Cancer Institute National Institutes of Health, Bethesda, MD 20892, USA
    Cell Host Microbe 8:260-70. 2010
    ..Regardless of the concentration, L2 vaccine-induced antibodies allow BM association but prevent association with the cell surface. Thus, we have revealed distinct mechanisms of vaccine-induced inhibition of virus infection in vivo...
  27. ncbi Efficient intracellular assembly of papillomaviral vectors
    Christopher B Buck
    Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, Maryland 20892-4263, USA
    J Virol 78:751-7. 2004
    ..The results suggest that the intracellular assembly of papillomavirus structural proteins around heterologous reporter plasmids is surprisingly promiscuous and may be driven primarily by a size discrimination mechanism...
  28. ncbi Conjugation of a self-antigen to papillomavirus-like particles allows for efficient induction of protective autoantibodies
    B Chackerian
    Laboratory of Cellular Oncology, National Institutes of Health, Bethesda, Maryland 20892-4040, USA
    J Clin Invest 108:415-23. 2001
    ..Together, these results suggest a potentially flexible method to efficiently generate autoantibodies against specific self-proteins that mediate arthritis and other diseases...
  29. ncbi Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and -18 infections
    Mahboobeh Safaeian
    Division of Cancer Epidemiology and Genetics, Infections and Immunoepidemiology Branch, National Cancer Institute, National Institutes of Health, 6120 Executive Blvd, Ste 550, Rockville, MD 20852, USA
    J Natl Cancer Inst 102:1653-62. 2010
    ..Infection with human papillomavirus (HPV) 16 or HPV18 elicits an antibody response, but whether the elicited antibodies protect women against subsequent infection by a homologous HPV type compared with seronegative women is unknown...
  30. ncbi Prophylactic human papillomavirus vaccines
    Douglas R Lowy
    Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    J Clin Invest 116:1167-73. 2006
    ..Unresolved issues include the most critical groups to vaccinate and when the vaccine's cost may be low enough for widespread implementation in the developing world, where 80% of cervical cancer occurs...
  31. ncbi Neutralization of human papillomavirus with monoclonal antibodies reveals different mechanisms of inhibition
    Patricia M Day
    Laboratory of Cellular Oncology, Center for Cancer Research, National Institutes of Health, Bethesda, MD 20892, USA
    J Virol 81:8784-92. 2007
    ..We conclude that neutralizing antibodies can inhibit HPV infection by multiple distinct mechanisms, and understanding these mechanisms can add insight to the HPV entry processes...
  32. ncbi Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial
    Allan Hildesheim
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA
    JAMA 298:743-53. 2007
    ..Viruslike particle human papillomavirus (HPV) vaccines were designed to prevent HPV infection and development of cervical precancers and cancer. Women with oncogenic HPV infections might consider vaccination as therapy...
  33. ncbi Mechanisms of human papillomavirus type 16 neutralization by l2 cross-neutralizing and l1 type-specific antibodies
    Patricia M Day
    Laboratory of Cellular Oncology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Virol 82:4638-46. 2008
    ..These findings suggest a dynamic model of virion-cell surface interactions that has implications for both evolution of viral serotypes and the efficacy of current and future HPV vaccines...
  34. ncbi In vivo longitudinal imaging of experimental human papillomavirus infection in mice with a multicolor fluorescence mini-endoscopy system
    Makoto Mitsunaga
    Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USA
    Cancer Prev Res (Phila) 4:767-73. 2011
    ..This method offers the ability to monitor experimental virus infections before and after intervention, thereby accelerating the development of appropriate prevention and therapy...
  35. ncbi Current understanding of the mechanism of HPV infection
    John T Schiller
    Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, MD 20892, USA
    Gynecol Oncol 118:S12-7. 2010
    ....
  36. ncbi Human papillomavirus infection and the primary and secondary prevention of cervical cancer
    Douglas R Lowy
    Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    Cancer 113:1980-93. 2008
    ..The manner in which vaccination and screening programs are integrated will need to be considered carefully so that they are efficient in reducing the overall incidence of cervical cancer...
  37. ncbi Seroprevalence and correlates of human papillomavirus 16/18 seropositivity among young women in Costa Rica
    Sarah Coseo
    Infections and Immunoepidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, 6120 Executive Blvd, EPS, Room 7079, Rockville, MD 20852, USA
    Sex Transm Dis 37:706-14. 2010
    ..We investigated HPV16 and 18 seroepidemiology among young, unvaccinated women aged between 18 and 25...
  38. ncbi Heparan sulfate-independent cell binding and infection with furin-precleaved papillomavirus capsids
    Patricia M Day
    Laboratory of Cellular Oncology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    J Virol 82:12565-8. 2008
    ..We conclude that the primary function of HSPG binding is to enable cell surface furin cleavage of L2 and that binding to a distinct cell surface receptor(s) is a subsequent step of papillomavirus infection...
  39. ncbi Human papillomavirus infection with multiple types: pattern of coinfection and risk of cervical disease
    Anil K Chaturvedi
    Infections and Immunoepidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, 6120 Executive Blvd, EPS 7072 Rockville, MD 20852, USA
    J Infect Dis 203:910-20. 2011
    ..We investigated coinfection patterns for 25 human papillomavirus (HPV) types and assessed the risk conferred by multiple HPV types toward cervical disease...
  40. ncbi The role of furin in papillomavirus infection
    Patricia M Day
    Laboratory of Cellular Oncology, National Cancer Institute, NIH, Bethesda, MD 20892, USA
    Future Microbiol 4:1255-62. 2009
    ..This work also has implications for further advances in papillomavirus vaccine development...
  41. ncbi Risk of miscarriage with bivalent vaccine against human papillomavirus (HPV) types 16 and 18: pooled analysis of two randomised controlled trials
    Sholom Wacholder
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, 6120 Executive Blvd, Rockville, MD 20852, USA
    BMJ 340:c712. 2010
    ..To assess whether vaccination against human papillomavirus (HPV) increases the risk of miscarriage...
  42. ncbi Vaccines to prevent infections by oncoviruses
    John T Schiller
    Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA
    Annu Rev Microbiol 64:23-41. 2010
    ..Efforts to develop KSHV vaccines have been more limited...
  43. ncbi Induction of autoantibodies to CCR5 in macaques and subsequent effects upon challenge with an R5-tropic simian/human immunodeficiency virus
    Bryce Chackerian
    Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Virol 78:4037-47. 2004
    ....
  44. ncbi Papillomaviruses infect cells via a clathrin-dependent pathway
    Patricia M Day
    Laboratory of Cellular Oncology, Division of Basic Sciences, National Cancer Institute, National Institutes of Health, Building 36, Room 1D-32, Bethesda, MD 20892, USA
    Virology 307:1-11. 2003
    ..Surprisingly, the kinetics of internalization were unusually slow for this mechanism, with the t(1/2) of entry of BPV-1 being approximately 4 h versus 5-15 min for a typical ligand...
  45. ncbi New associations of human papillomavirus, Simian virus 40, and Epstein-Barr virus with human cancer
    May Wong
    Biological Carcinogenesis Branch, National Cancer Institute, Bethesda, MD 20892, USA
    J Natl Cancer Inst 94:1832-6. 2002
  46. ncbi Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2
    Diana V Pastrana
    Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, MD 20892 4263, USA
    Virology 337:365-72. 2005
    ..BPV1 L2 was exceptionally effective at inducing cross-neutralizing antibodies to these shared epitopes...
  47. ncbi Maturation of papillomavirus capsids
    Christopher B Buck
    Laboratory of Cellular Oncology, Building 37, Room 4106, 9000 Rockville Pike, Bethesda, MD 20892-4263, USA
    J Virol 79:2839-46. 2005
    ..Despite their obvious morphological differences, mature and immature capsids are similarly neutralizable by various L1- and L2-specific antibodies...
  48. ncbi Establishment of papillomavirus infection is enhanced by promyelocytic leukemia protein (PML) expression
    Patricia M Day
    Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 101:14252-7. 2004
    ..The results identify a role for PML in the enhancement of viral infectivity in the early part of the life cycle. We propose a model in which L2 chaperones the viral genome to ND10 to efficiently initiate viral transcription...
  49. ncbi Papillomavirus virus-like particles induce cytokines characteristic of innate immune responses in plasmacytoid dendritic cells
    Petra Lenz
    Laboratory of Cellular Oncology, National Cancer Institute, National Institutes of Health, Bethesda, USA
    Eur J Immunol 35:1548-56. 2005
    ..Finally, CpG-activated pDC, but not pDC exposed to HPV16 VLP, activated lymphocytes to secrete IL-10 and low levels of IFN-gamma. Together these findings suggest a possible immunogenic effect of pDC in the setting of VLP vaccination...
  50. ncbi In vitro biological activities of the E6 and E7 genes vary among human papillomaviruses of different oncogenic potential
    M S Barbosa
    Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, Maryland 20892
    J Virol 65:292-8. 1991
    ..These same factors may, in part, account for the apparent difference in oncogenic potential between these viruses...
  51. ncbi Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine
    C D Harro
    Center for Immunization Research, Department of International Medicine, School of Hygiene and Public Health, The Johns Hopkins University, Baltimore, MD, USA
    J Natl Cancer Inst 93:284-92. 2001
    ....
  52. ncbi Mucosal delivery of human papillomavirus pseudovirus-encapsidated plasmids improves the potency of DNA vaccination
    B S Graham
    Viral Pathogenesis Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA
    Mucosal Immunol 3:475-86. 2010
    ..HPV PsV encapsidation of plasmid DNA is a novel strategy for mucosal immunization that could provide new vaccine options for selected mucosal pathogens...
  53. ncbi Arrangement of L2 within the papillomavirus capsid
    Christopher B Buck
    Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892 5624, USA
    J Virol 82:5190-7. 2008
    ..This structural information should facilitate investigation of L2 function during the assembly and entry phases of the papillomavirus life cycle...
  54. ncbi The initial steps leading to papillomavirus infection occur on the basement membrane prior to cell surface binding
    Rhonda C Kines
    Laboratory of Cellular Oncology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 106:20458-63. 2009
    ....
  55. ncbi Role of heparan sulfate in attachment to and infection of the murine female genital tract by human papillomavirus
    Katherine M Johnson
    Laboratory of Cellular Oncology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Virol 83:2067-74. 2009
    ..We speculate that cutaneous HPVs, such as HPV5, and genital mucosal HPVs, such as HPV16 and -31, may have evolved to recognize different forms of HSPGs to enable them to preferentially infect keratinocytes at different anatomical sites...
  56. ncbi Interaction of papillomavirus virus-like particles with human myeloid antigen-presenting cells
    Petra Lenz
    Laboratory of Cellular Oncology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-4040, USA
    Clin Immunol 106:231-7. 2003
    ..Our results indicate that VLPs target multiple cells of the immune system, which helps to account for VLPs being so effective in priming humoral and cellular immune responses even in the absence of adjuvant...
  57. ncbi Cleavage of the papillomavirus minor capsid protein, L2, at a furin consensus site is necessary for infection
    Rebecca M Richards
    Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 103:1522-7. 2006
    ..However, to our knowledge, furin has not been previously implicated in the viral entry process. This step is potentially a target for PV inhibition...
  58. ncbi Determinants of seropositivity among HPV-16/18 DNA positive young women
    Carolina Porras
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA
    BMC Infect Dis 10:238. 2010
    ..We evaluated determinants of seropositivity among 646 women infected with HPV-16 and/or HPV-18...
  59. ncbi Combined prophylactic and therapeutic cancer vaccine: enhancing CTL responses to HPV16 E2 using a chimeric VLP in HLA-A2 mice
    Jiahua Qian
    Vaccine Branch, NCI, National Naval Medical Center, Bldg 8, Bethesda, MD 20892, USA
    Int J Cancer 118:3022-9. 2006
    ....
  60. ncbi Human papillomavirus serology and the risk of esophageal and gastric cancers: results from a cohort in a high-risk region in China
    Farin Kamangar
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA
    Int J Cancer 119:579-84. 2006
    ..4). For HPV 73, these figures were 1.3 (0.6-2.5), 1.2 (0.6-2.3) and 0.9 (0.4-2.1). The results of this study do not support a major role for HPV 16, HPV 18 and HPV 73 in the etiology of esophageal and gastric cancers in Linxian, China...
  61. ncbi Human alpha-defensins block papillomavirus infection
    Christopher B Buck
    Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute/NIH, Bethesda, MD 20892-4263, USA
    Proc Natl Acad Sci U S A 103:1516-21. 2006
    ....
  62. ncbi Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan
    Jeffrey N Roberts
    Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 4263, USA
    Nat Med 13:857-61. 2007
    ..In contrast, carrageenan, a polysaccharide present in some vaginal lubricants, prevented infection even in the presence of N-9, suggesting that carrageenan might serve as an effective topical HPV microbicide...
  63. ncbi Generation of HPV pseudovirions using transfection and their use in neutralization assays
    Christopher B Buck
    Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
    Methods Mol Med 119:445-62. 2005
    ..Antibody-mediated PsV neutralization is detected by a reduction in SEAP activity. The neutralization assay has similar analytic sensitivity to, and higher specificity than, a standard VLP-based enzyme-linked immunosorbent assay (ELISA)...
  64. ncbi Effect of Pap smear collection and carrageenan on cervicovaginal human papillomavirus-16 infection in a rhesus macaque model
    Jeffrey N Roberts
    Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Natl Cancer Inst 103:737-43. 2011
    ..Therefore, we determined whether a cytology specimen collection procedure (Pap smear), which disrupts the epithelium by design, renders the cervix more susceptible to HPV infection in a primate model...
  65. ncbi Human papillomavirus type 16 infection and squamous cell carcinoma of the head and neck in never-smokers: a matched pair analysis
    Kristina R Dahlstrom
    Departments of Head and Neck Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 9:2620-6. 2003
    ..Furthermore, HPV-16 infection does not appear to be more common in never-smokers than ever-smokers with SCCHN...
  66. ncbi Cellular immune responses to HPV-18, -31, and -53 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles
    Ligia A Pinto
    HPV Immunology Laboratory, SAIC-Frederick, Inc./NCI-Frederick, Frederick Building 469, Room 120, Frederick, MD 21702, USA
    Virology 353:451-62. 2006
    ..In summary, PBMC from HPV-16 VLP vaccine recipients can respond to L1VLP from heterologous HPV types, suggesting the presence of conserved T cell epitopes...
  67. ncbi Heterologous boosting increases immunogenicity of chimeric papillomavirus virus-like particle vaccines
    Diane M Da Silva
    Cancer Immunology Program, Department of Microbiology and Immunology, Cardinal Bernardin Cancer Center, Loyola University Chicago, 2160 S. First Avenue, Maywood, IL, 60153, USA
    Vaccine 21:3219-27. 2003
    ..The data indicate that the use of different cVLP types for prime/boost regimens is a promising strategy to increase the efficacy and usefulness of cVLP-based vaccines for the treatment of cervical neoplasia...
  68. ncbi Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles
    Denise Nardelli-Haefliger
    Department of Gynecology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    J Natl Cancer Inst 95:1128-37. 2003
    ....
  69. ncbi Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles
    Ligia A Pinto
    SAIC Frederick, Inc National Cancer Institute, Building 469, Room 120, Frederick, MD 21702, USA
    J Infect Dis 188:327-38. 2003
    ..Future efficacy studies are needed to evaluate whether and/or how VLP vaccines confer protection against genital HPV infection and associated disease...
  70. ncbi Prevention of cancer through immunization: Prospects and challenges for the 21st century
    Ian H Frazer
    Diamantina Institute for Cancer Immunology and Metabolic Medicine, Princess Alexandra Hospital, Woolloongabba, Queensland, Australia
    Eur J Immunol 37:S148-55. 2007
    ....
  71. ncbi Cytokine and chemokine profiles following vaccination with human papillomavirus type 16 L1 Virus-like particles
    Alfonso Garcia Pineres
    HPV Immunology Laboratory, SAIC Frederick, Inc NCI Frederick, Frederick, Maryland 21702, USA
    Clin Vaccine Immunol 14:984-9. 2007
    ..Cytokine profiling studies using samples from efficacy trials may provide important information about discriminators of long-term protection against HPV...
  72. ncbi Humoral and cellular immune responses to airway immunization of mice with human papillomavirus type 16 virus-like particles and mucosal adjuvants
    Véronique Revaz
    Institute of Microbiology, Centre Hospitalier Universitaire Vaudois, CH 1011 Lausanne, Switzerland
    Antiviral Res 76:75-85. 2007
    ....
  73. ncbi Immune responses induced by lower airway mucosal immunisation with a human papillomavirus type 16 virus-like particle vaccine
    Denise Nardelli-Haefliger
    Department of Gynecology, Centre Hospitalier Universitaire Vaudois, CH 1011 Lausanne, Switzerland
    Vaccine 23:3634-41. 2005
    ..Our data suggest that aerosol administration of HPV VLPs may represent a potential alternative to parenteral injection...
  74. ncbi Evaluation of two types of sponges used to collect cervical secretions and assessment of antibody extraction protocols for recovery of neutralizing anti-human papillomavirus type 16 antibodies
    Troy J Kemp
    HPV Immunology Laboratory, SAIC Frederick, Inc, NCI Frederick, Frederick, MD 21702, USA
    Clin Vaccine Immunol 15:60-4. 2008
    ..2% and 93.5%, respectively, suggesting that Merocel sponges are more appropriate for specimen collection. The SEAPNA can be applied to determine the surrogates of protection and to examine the durability of protection at the cervix...
  75. ncbi p53 codon 72 polymorphism associated with risk of human papillomavirus-associated squamous cell carcinoma of the oropharynx in never-smokers
    Xuemei Ji
    Department of Head and Neck Surgery, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Carcinogenesis 29:875-9. 2008
    ..5; 95% CI, 4.8-106.2). These findings suggest that p53 codon 72 variant genotypes modify the risk of HPV16-associated SCCOP and may be markers of genetic susceptibility to HPV16-associated SCCOP, especially among never-smokers...
  76. ncbi Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2
    Hannah H Alphs
    Departments of Pathology Oncology Gynecology and Obstetrics, Johns Hopkins School of Medicine, Baltimore, MD 21231
    Proc Natl Acad Sci U S A 105:5850-5. 2008
    ..If provided in the appropriate context, therefore, HPV16 L2 17-36 might be used in a totally synthetic cross-protective HPV vaccine...
  77. ncbi A population-based study of cervical carcinoma and HPV infection in Latvia
    Ilvars Silins
    Oncology Center of Latvia, Riga
    Gynecol Oncol 93:484-92. 2004
    ..4% of cervical cancers in age groups eligible for screening. HPV type 16 infection was the most important risk factor for cervical cancer in Latvia, with a population-attributable risk percent for all ages of 58.5%...
  78. ncbi Evaluation of systemic and mucosal anti-HPV16 and anti-HPV18 antibody responses from vaccinated women
    Troy J Kemp
    HPV Immunology Laboratory, SAIC Frederick Inc, NCI Frederick, Building 469, Room 120, Frederick, MD 21702, USA
    Vaccine 26:3608-16. 2008
    ....
  79. ncbi A membrane-destabilizing peptide in capsid protein L2 is required for egress of papillomavirus genomes from endosomes
    Nadine Kämper
    Institute of Medical Microbiology and Hygiene, Johannes Gutenberg Universitat Mainz, Germany
    J Virol 80:759-68. 2006
    ..Furthermore, the characteristic of this peptide differs from the classical virus-encoded membrane-penetrating peptides...
  80. ncbi HPV-16 L1 VLP vaccine elicits a broad-spectrum of cytokine responses in whole blood
    Ligia A Pinto
    SAIC Frederick, Inc NCI Frederick, Room 120, Building 469, Frederick, MD 21702, USA
    Vaccine 23:3555-64. 2005
    ....
  81. ncbi Chapter 30: HPV vaccines and screening in the prevention of cervical cancer; conclusions from a 2006 workshop of international experts
    Thomas C Wright
    Department of Pathology, Columbia University, 630 W 168th Street, NY 10032, USA
    Vaccine 24:S3/251-61. 2006
    ..In this summary, we summarize the opinions of this expert group on how these advances can be introduced to provide the maximum benefit to women and to reduce the global burden of cervical cancer...
  82. ncbi Chapter 29: Knowledge gaps and priorities for research on prevention of HPV infection and cervical cancer
    Eduardo L Franco
    Division of Cancer Epidemiology, Departments of Oncology and Epidemiology and Biostatistics, McGill University, 546 Pine Avenue West, Montreal, Quebec, Canada
    Vaccine 24:S3/242-9. 2006
    ..The field of HPV and cervical cancer prevention has never been so multi-disciplinary. A new era has begun and the challenges are many...
  83. ncbi Epidemiology of genital Chlamydia trachomatis infection among young women in Costa Rica
    Carolina Porras
    Proyecto Epidemiologico Guanacaste, Fundacion INCIENSA, San Jose, Costa Rica
    Sex Transm Dis 35:461-8. 2008
    ..To investigate Chlamydia trachomatis (Ct) epidemiology among 5829 women 18 to 25 years old, in Costa Rica...
  84. ncbi Virus-like display of a neo-self antigen reverses B cell anergy in a B cell receptor transgenic mouse model
    Bryce Chackerian
    Department of Molecular Genetics and Microbiology, School of Medicine, University of New Mexico, Albuquerque, NM 87131, USA
    J Immunol 180:5816-25. 2008
    ..Moreover, immunization with VLP-HEL reversed B cell anergy in vivo in an adoptive transfer model. Thus, Ag multivalency and T help cooperate to reverse B cell anergy, a major mechanism of B cell tolerance...
  85. ncbi Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica
    Rolando Herrero
    Proyecto Epidemiologico Guanacaste, Fundacion INCIENSA, Torre La Sabana, 300 Oeste del ICE, Piso 7, Sabana Norte, San Jose, Costa Rica
    Vaccine 26:4795-808. 2008
    ..4% agreement for all types, kappa 0.59). Follow up will continue with yearly or more frequent examinations for at least 4 years for each participant...
  86. ncbi Human papillomavirus type 16 entry: retrograde cell surface transport along actin-rich protrusions
    Mario Schelhaas
    Institute of Biochemistry, ETH Zurich, Zurich, Switzerland
    PLoS Pathog 4:e1000148. 2008
    ..We found that transport along actin protrusions significantly enhanced HPV-16 infection in sparse tissue culture, cells suggesting a role for in vivo infection of basal keratinocytes during wound healing...
  87. ncbi A novel polyherbal microbicide with inhibitory effect on bacterial, fungal and viral genital pathogens
    G P Talwar
    Talwar Research Foundation, E 8, Neb Valley, Neb Sarai, New Delhi, India
    Int J Antimicrob Agents 32:180-5. 2008
    ..Basant has the potential of regressing vulvovaginal candidiasis and preventing N. gonorrhoeae, HIV and HPV infections...